Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)

Status:	Not yet recruiting
Conditions:	Influenza
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	Any
Updated:	2/27/2016
Start Date:	January 2016
End Date:	April 2017
Contact:	Novartis Drug Information Services
Phone:	18002447668

Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to Either the Same or Alternate Type of Vaccine, Adjuvanted or Non-adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV or QIV), Administered to Subjects Previously Vaccinated in Trial V118_05 (NCT01964989)

Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine
Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously vaccinated in
Trial V118_05. Subjects will receive either the Same or Alternate Type of Vaccine.

Inclusion Criteria:

- Male or female subject who has completed their last visit in trial V118_05.

- Subject's parent/legal guardian has voluntarily given written informed consent after
the nature of the study has been explained according to local regulatory
requirements, prior to study enter

Exclusion Criteria:

- Individuals recently vaccinated against influenza

- Subjects with contraindications to receive influenza vaccines

- Please contact the site for additional eligibility criteria.

We found this trial at

sites

Novartis Investigative Site

Metairie, Louisiana 70006

from

Metairie, LA